Successful Resection of Cisplatin-Resistant Renal Pelvic Cancer after the Administration of Pembrolizumab as Second-Line Therapy

Pembrolizumab has been used as a second-line systemic therapy for urothelial carcinoma. We herein report a case of cisplatin-resistant renal-pelvic urothelial carcinoma that was successfully resected after pembrolizumab treatment. A 74-year-old woman was referred to our hospital for further examinat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawahara, Takashi, Mochizuki, Taku, Sugimura, Rumiko, Izumi, Koji, Kuroda, Shinnosuke, Miyoshi, Yasuhide, Nakaigawa, Noboru, Yao, Masahiro, Tanabe, Mikiko, Uemura, Hiroji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696768/
https://www.ncbi.nlm.nih.gov/pubmed/31427950
http://dx.doi.org/10.1159/000501715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696768/
https://www.ncbi.nlm.nih.gov/pubmed/31427950
http://dx.doi.org/10.1159/000501715

Ejemplares similares